Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis [PDF]
Journal of Comparative Effectiveness ResearchAim: Compared with uncomplicated urinary tract infections (UTIs), complicated UTIs (cUTIs) including acute pyelonephritis (AP) presentwith significant morbidity, a higher risk of treatment failure and typically require longer courses of treatment, or ...
Florian Wagenlehner +8 more
doaj +2 more sources
Antimicrobial activity of cephamycins and β-lactam/β-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula [PDF]
Scientific ReportsThis study investigated the in vitro antimicrobial activity of cephamycins and novel β-lactam/β-lactamase inhibitor combinations, against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates.
Yu Mi Wi +5 more
doaj +2 more sources
Nephrotoxicity of New Antibiotics: A Systematic Review [PDF]
ToxicsDrug-induced nephrotoxicity is a common and serious problem in clinical practice. We conducted a systematic review of studies reporting nephrotoxicity events associated with antibiotics approved since 2018.
Panagiotis Stathopoulos +3 more
doaj +2 more sources
Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations [PDF]
GMS Hygiene and Infection ControlThis review explore the rise of multidrug-resistant (MDR) Gram-negative bacteria, highlighting β-lactamase inhibitor combinations as crucial therapeutic options.
Marzooka, Kazi-Chishti +4 more
doaj +2 more sources
Evaluating the health economic impact of cefepime/enmetazobactam in complicated urinary tract infections in the German setting: a cost analysis from payer perspective. [PDF]
InfectionRöder J +8 more
europepmc +4 more sources
Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy. [PDF]
Indian J Med ResChandra P.
europepmc +3 more sources
Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications [PDF]
Current Therapeutic ResearchObjective: This analysis aimed to provide a mechanistic understanding and an evaluation of the clinical relevance of pharmacokinetic drug-drug interactions (DDIs) associated with drugs approved by the Food and Drug Administration in 2024.
Jingjing Yu, MD, PhD +4 more
doaj +2 more sources
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants. [PDF]
J Antimicrob ChemotherCrema A +3 more
europepmc +2 more sources
Antimicrobial Agents and Chemotherapy, 2021 The use of carbapenem antibiotics to treat infections caused by Enterobacterales expressing increasingly aggressive extended-spectrum β-lactamases (ESBLs) has contributed to the emergence of carbapenem resistance. Enmetazobactam is a novel ESBL inhibitor being developed in combination with cefepime as a carbapenem ...
Philipp Knechtle +4 more
openalex +5 more sources